NZ603531A - Alcohol-resistant formulations - Google Patents

Alcohol-resistant formulations

Info

Publication number
NZ603531A
NZ603531A NZ603531A NZ60353111A NZ603531A NZ 603531 A NZ603531 A NZ 603531A NZ 603531 A NZ603531 A NZ 603531A NZ 60353111 A NZ60353111 A NZ 60353111A NZ 603531 A NZ603531 A NZ 603531A
Authority
NZ
New Zealand
Prior art keywords
gums
dosage form
carboxymethylcellulose
alcohol
resistance
Prior art date
Application number
NZ603531A
Other languages
English (en)
Inventor
Ehab Hamed
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of NZ603531A publication Critical patent/NZ603531A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
NZ603531A 2010-05-11 2011-05-09 Alcohol-resistant formulations NZ603531A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33352110P 2010-05-11 2010-05-11
PCT/US2011/035767 WO2011143118A2 (en) 2010-05-11 2011-05-09 Alcohol-resistant formulations

Publications (1)

Publication Number Publication Date
NZ603531A true NZ603531A (en) 2014-08-29

Family

ID=44344024

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603531A NZ603531A (en) 2010-05-11 2011-05-09 Alcohol-resistant formulations

Country Status (10)

Country Link
US (2) US20130202705A1 (enExample)
EP (1) EP2568969A2 (enExample)
JP (1) JP5894720B2 (enExample)
CN (1) CN102883713B (enExample)
AU (1) AU2011253216B2 (enExample)
CA (1) CA2798700C (enExample)
IL (1) IL222637A (enExample)
MX (1) MX2012013021A (enExample)
NZ (1) NZ603531A (enExample)
WO (1) WO2011143118A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
CN103893146A (zh) * 2012-12-25 2014-07-02 天津药物研究院 含福多司坦缓释剂型
WO2014197744A1 (en) * 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9561187B1 (en) * 2014-02-03 2017-02-07 CMAX Technologies, Inc. Sustained release metoprolol formulations
DK3164117T3 (da) 2014-07-03 2023-12-04 SpecGx LLC Misbrugssikre formuleringer med øjeblikkelig frigivelse omfattende ikke-cellulose-polysaccharider
US20180344649A1 (en) 2015-09-29 2018-12-06 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
AR113993A1 (es) 2017-12-21 2020-07-08 Faes Farma Sa Formulación una vez al día de hidrosmina
CN110812337B (zh) * 2018-08-08 2022-04-12 上海宣泰医药科技股份有限公司 一种通过流化床制粒法制备氨基己酸片剂的方法
CN110812332B (zh) * 2018-08-10 2022-09-02 北京普德康利医药科技发展有限公司 一种双氯芬酸钠咽部滞留颗粒
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
EP1689373B1 (en) * 2003-10-10 2019-04-03 Ethypharm Sustained-release microgranules containing ginkgo biloba extract and the process for manufacturing these
US20070092573A1 (en) * 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
WO2007048223A2 (en) * 2005-10-25 2007-05-03 Pharmascience Inc. A gastric retention drug delivery system
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
JP2008007293A (ja) * 2006-06-30 2008-01-17 Komori Corp 搬送装置
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
DK2200593T5 (en) * 2007-09-13 2016-12-12 Cima Labs Inc Hog-resistant pharmaceutical formulation

Also Published As

Publication number Publication date
JP2013526521A (ja) 2013-06-24
AU2011253216A1 (en) 2012-11-29
EP2568969A2 (en) 2013-03-20
US20130202705A1 (en) 2013-08-08
CA2798700C (en) 2018-08-21
WO2011143118A2 (en) 2011-11-17
MX2012013021A (es) 2012-12-17
CN102883713A (zh) 2013-01-16
JP5894720B2 (ja) 2016-03-30
AU2011253216B2 (en) 2016-10-20
WO2011143118A3 (en) 2012-07-05
IL222637A0 (en) 2012-12-31
US20190133924A1 (en) 2019-05-09
IL222637A (en) 2017-04-30
CN102883713B (zh) 2016-08-03
CA2798700A1 (en) 2011-11-17

Similar Documents

Publication Publication Date Title
NZ603531A (en) Alcohol-resistant formulations
NZ602075A (en) Abuse-resistant formulations
JP2013514386A5 (enExample)
NZ592325A (en) Extended release oral acetaminophen/tramadol dosage form
TW200806338A (en) Pharmaceutical formulations
GB2495676A (en) Use of binders for manufacturing storage stable formulations
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
JP2012255026A5 (enExample)
MY151240A (en) Solid pharmaceutical formulations comprising bibw 2992
NZ608239A (en) Aqueous drug delivery system comprising off - flavor masking agent
MX2011000884A (es) Medicamento apetecible de administracion oral bajo forma solida.
MX363495B (es) Proceso de manufacturacion de una forma de dosificacion multifasica de rapida disolucion liofilizada.
JP2011241218A5 (enExample)
PH12015500823A1 (en) Modified release formulations for oprozomib
MY184400A (en) Solid pharmaceutical preparation containing levothyroxine
EP4233874A3 (en) Acetylsalicylic acid for reducing the risk of a thromboembolic event
WO2012052834A3 (en) Multiple unit particulate system comprising metoprolol succinate
TR201001417A1 (tr) Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu
WO2012055947A3 (de) Herstellung orodispersibler filme
JP2015120758A5 (enExample)
IN2014CN02343A (en) Oral formulations containing hyaluronic acid for sustained drug release
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
WO2015011653A9 (en) pH RESPONSIVE ORAL POLYMERIC PHARMACEUTICAL DOSAGE FORM
WO2012068076A3 (en) Pharmaceutical formulations containing soluble drugs
WO2012018742A3 (en) Dextromethorphan antitussive compositions

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2016 BY DENNEMEYER + CO

Effective date: 20150423

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2017 BY DENNEMEYER + CO

Effective date: 20160422

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2018 BY DENNEMEYER + CO

Effective date: 20170427

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2019 BY DENNEMEYER + CO

Effective date: 20180423

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2020 BY DENNEMEYER + CO.

Effective date: 20190419

LAPS Patent lapsed